Амоксициллин/клавуланат в современных режимах антибиотикотерапии обострений хронической обструктивной болезни легких
Амоксициллин/клавуланат в современных режимах антибиотикотерапии обострений хронической обструктивной болезни легких
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Список литературы
1. Сидоренко С.В. Механизмы резистентности микроорганизмов. В кн.: Страчунский Л.С., Белоусов Ю.Б., Козлов С.Н., под ред. Практическое руководство по антиинфекционной химиотерапии. М.: Боргес, 2002.
2. Bush K. Beta-lactamase inhibitors from laboratory to clinic. Clin Microbiol Rev 1988; 1: 109–23.
3. Du Bois SK, Marriott MS, Amyes SG. TEM- and SHV-derived extended-spectrum β-lactamases: relationship between selection, structure and function. J Antimicrob Chemother 1995; 35: 7–22.
4. Bush K, Jacoby GA, Medeiros AA. Functional classification scheme for β-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother 1995; 39: 1211–33.
5. Abraham E.P, Chain E. An enzyme from bacteria able to destroy penicillin. Nature 1940; 373: 837.
6. Reading C, Cole M. Ctavulanic acid: a beta-lactamase-inhibiting beta-lactam from Streptomyces clavuligerus. Antimicrob Agents Chemother 1977; 11 (5): 852–7.
7. Datta N, Kontomichalou P. Penicillinase synthesis controlled by infectious R factor in Enterobacteriaceae. Nature 1965; 208: 239–41.
8. Chambers HF. Other beta-lactam antibiotics. In: Mandell GL, Bennet JE, Dolin R, editors. Principles and Practice of Infectious Diseases. Churchill Livingstone, 6th edition, 2004; p. 311–8.
9. Bush K. Other b-lactam antibiotics. In: Finch RG, Greenwood D, Norrby SR, Whitley RJ, editors. Antibiotic and Chemotherapy. Anti-infective agent and their use in therapy. Churchill Livingstone, 8th edition. 2003, p. 259–78.
10. Neu HC, Wilson, APR. Gruneberg RN. Amoxycillin/clavulanic acid: a review of its efficacy in over 38,500 patients from 1979 to 1992. J Chemother 1993; 5: 67–93.
11. Fuhrman C, Delmas M. Epidemiology of chronic obstructive pulmonary disease in France. Rev Mal Respir 2010; 27 (2): 160–8.
12. Roche N., Huchon G. Epidemiology of chronic obstructive pulmonary disease. Rev Prat 2004; 54 (13): 1408–13.
13. Hansen J, Pedersen L, Overvad K. Prevalence of chronic obstructive pulmonary disease-secondary publication. Ugeskr Laeger 2009; 171 (41): 2986–8.
14. World Health Report 2000. Health systems: improving performance. Annex table 3. 2000 World Health Organization. Geneva, Switzerland.
15. Mapel D, Chen J, George D et al. The cost of chronic obstructive pulmonary disease and its effects on managed care. Manag Care Interface 2004; 17 (4): 61–6.
16. Страбыкина П.Е. Эффективность скринингового метода обследования для выявления нарушений бронхиальной проходимости. Бюлл. СО РАМН 2006; 122: 168–71.
17. Makris D, Moschandreas J, Damianaki A et al. Exacerbations and lung function decline in COPD: new insights in current and ex-smokers. Respir Med 2007; 101: 1305–12.
18. Niewoehner D. Relation of Chronic Obstructive Pulmonary Disease Exacerbations to FEV(1) - An Intricate Tango. Respiration 2009; 77 (2): 229–35.
19. Dusser D. Chronic obstructive pulmonary disease exacerbations and their impact on the long-term natural history of the disease. Presse Med 2008; 37 (11): 1599–603.
20. Sethi S, Murphy T. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med 2008; 359: 2355.
21. Murphy T, Parameswaran G. Moraxella catarrhalis, a human respiratory tract pathogen. Clin Infect Dis 2009; 49 (1): 124–31.
22. Murphy T, Brauer A, Eschberger K et al. Pseudomonas aeruginosa in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008; 177 (8): 853–60.
23. De Serres G, Lampron N, La Forge J et al. Importance of viral and bacterial infections in chronic obstructive pulmonary disease exacerbations. J Clin Virol 2009; 46 (2): 129–33.
24. Kherad O, Rutschmann O. Viral Infections as a Cause of Chronic Obstructive Pulmonary Disease (COPD) Exacerbation. Praxis 2010; 99 (4): 235–240.
25. Lode H, Allewelt M, Balk S et al. A prediction model for bacterial etiology in acute exacerbations of COPD. Infection 2007; 35: 143–9.
26. Canut A, Mart_n-Herrero JE, Labora A, Maortua H. What are the most appropriate antibiotics for the treatment of acute exacerbation of chronic obstructive pulmonary disease? A therapeutic outcomes model. J of Antimicrob Chemother 2007; 60: 605–12.
27. Thornsberry C, Sahm D, Kelly L et al. Regional trends in antimicrobial resistance among clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States: results from the TRUST Surveillance Program, 1999–2000. Clin Infect Dis 2002; 34 (Suppl. 1): 4–16.
28. Jacobs M, Felmingham D, Appelbaum P et al. The Alexander Project 1998–2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. J Antimicrob Chemother 2003; 52 (2): 229–46.
29. Козлов Р.С., Сивая О.В., Шпынев К.В. и др. Антибиотикорезистентность Streptococcus pneumoniae в России в 1999–2005 гг.: результаты многоцентровых проспективных исследований Пегас I и Пегас II. Клин. микробиол. антимикроб. химиотер. 2006; 8 (1): 33–47.
30. White A, Kaye1 C, Poupard J et al. Augmentin® (amoxicillin/clavulanate) in the treatment of community-acquired respiratory tract infection: a review of the continuing development of an innovative antimicrobial agent. J Antimicrob Chemother 2004; 53 (Suppl. 1): 3–20.
31. Calvo A, Amores R, Valero E et al. Activity of different antimicrobial agents against penicillin-resistant Streptococcus pneumoniae. Rev Esp Quimioter 2001; 14: 345–50.
32. Eller J, Ede A, Schaberg T et al. Infective exacerbations of chronic bronchitis: relation between bacteriologic etiology and lung function. Chest 1998; 113: 1542–8.
33. Siempos I, Dimopoulos G, Korbila I et al. Macrolides, quinolones, and amoxicillin/clavulanate for chronic bronchitis: a meta-analysis. Eur Respir J 2007; Доступно на: http://www.antibiotic.ru/print.php?sid=1538
34. Синопальников А.И., Козлов Р.С., Романовских А.Г., Рачина С.А. Инфекционное обострение ХОБЛ: практические рекомендации по диагностике, лечению и профилактике. Рос. мед. вести. 2006; XI (№1): 4–18.
35. Рачина С.А., Зайцев А.А. Фармакоэпидемиологические исследования антибактериальных препаратов при внебольничных инфекциях дыхательных путей. Глава в книге: Руководство для врачей «Внебольничные инфекции дыхательных путей: диагностика и лечение». М.: М-Вести, 2008.
36. Рачина С.А., Фокин А.А., Ишмухаметов А.А. и др. Анализ динамики поквартального потребления антибактериальных препаратов для системного применения в амбулаторном и госпитальном секторах в РФ в 2004 г. Ремедиум. 2006; 11: 24–9.
37. Ferech M, Coenen S, Dvorakova K et al. European Surveillance of Antimicrobial Consumption (ESAC): outpatient penicillin use in Europe. J Antimicrob Chemother 2006; 58 (2): 408–12.
38. Metz-Gercek S, Maieron A, Strau R et al. Ten years of antibiotic consumption in ambulatory care: Trends in prescribing practice and antibiotic resistance in Austria. BMC Infectious Diseases 2009. Доступно на: http://www.biomedcentral.com/1471–2334/9/61.
2. Bush K. Beta-lactamase inhibitors from laboratory to clinic. Clin Microbiol Rev 1988; 1: 109–23.
3. Du Bois SK, Marriott MS, Amyes SG. TEM- and SHV-derived extended-spectrum β-lactamases: relationship between selection, structure and function. J Antimicrob Chemother 1995; 35: 7–22.
4. Bush K, Jacoby GA, Medeiros AA. Functional classification scheme for β-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother 1995; 39: 1211–33.
5. Abraham E.P, Chain E. An enzyme from bacteria able to destroy penicillin. Nature 1940; 373: 837.
6. Reading C, Cole M. Ctavulanic acid: a beta-lactamase-inhibiting beta-lactam from Streptomyces clavuligerus. Antimicrob Agents Chemother 1977; 11 (5): 852–7.
7. Datta N, Kontomichalou P. Penicillinase synthesis controlled by infectious R factor in Enterobacteriaceae. Nature 1965; 208: 239–41.
8. Chambers HF. Other beta-lactam antibiotics. In: Mandell GL, Bennet JE, Dolin R, editors. Principles and Practice of Infectious Diseases. Churchill Livingstone, 6th edition, 2004; p. 311–8.
9. Bush K. Other b-lactam antibiotics. In: Finch RG, Greenwood D, Norrby SR, Whitley RJ, editors. Antibiotic and Chemotherapy. Anti-infective agent and their use in therapy. Churchill Livingstone, 8th edition. 2003, p. 259–78.
10. Neu HC, Wilson, APR. Gruneberg RN. Amoxycillin/clavulanic acid: a review of its efficacy in over 38,500 patients from 1979 to 1992. J Chemother 1993; 5: 67–93.
11. Fuhrman C, Delmas M. Epidemiology of chronic obstructive pulmonary disease in France. Rev Mal Respir 2010; 27 (2): 160–8.
12. Roche N., Huchon G. Epidemiology of chronic obstructive pulmonary disease. Rev Prat 2004; 54 (13): 1408–13.
13. Hansen J, Pedersen L, Overvad K. Prevalence of chronic obstructive pulmonary disease-secondary publication. Ugeskr Laeger 2009; 171 (41): 2986–8.
14. World Health Report 2000. Health systems: improving performance. Annex table 3. 2000 World Health Organization. Geneva, Switzerland.
15. Mapel D, Chen J, George D et al. The cost of chronic obstructive pulmonary disease and its effects on managed care. Manag Care Interface 2004; 17 (4): 61–6.
16. Страбыкина П.Е. Эффективность скринингового метода обследования для выявления нарушений бронхиальной проходимости. Бюлл. СО РАМН 2006; 122: 168–71.
17. Makris D, Moschandreas J, Damianaki A et al. Exacerbations and lung function decline in COPD: new insights in current and ex-smokers. Respir Med 2007; 101: 1305–12.
18. Niewoehner D. Relation of Chronic Obstructive Pulmonary Disease Exacerbations to FEV(1) - An Intricate Tango. Respiration 2009; 77 (2): 229–35.
19. Dusser D. Chronic obstructive pulmonary disease exacerbations and their impact on the long-term natural history of the disease. Presse Med 2008; 37 (11): 1599–603.
20. Sethi S, Murphy T. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med 2008; 359: 2355.
21. Murphy T, Parameswaran G. Moraxella catarrhalis, a human respiratory tract pathogen. Clin Infect Dis 2009; 49 (1): 124–31.
22. Murphy T, Brauer A, Eschberger K et al. Pseudomonas aeruginosa in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008; 177 (8): 853–60.
23. De Serres G, Lampron N, La Forge J et al. Importance of viral and bacterial infections in chronic obstructive pulmonary disease exacerbations. J Clin Virol 2009; 46 (2): 129–33.
24. Kherad O, Rutschmann O. Viral Infections as a Cause of Chronic Obstructive Pulmonary Disease (COPD) Exacerbation. Praxis 2010; 99 (4): 235–240.
25. Lode H, Allewelt M, Balk S et al. A prediction model for bacterial etiology in acute exacerbations of COPD. Infection 2007; 35: 143–9.
26. Canut A, Mart_n-Herrero JE, Labora A, Maortua H. What are the most appropriate antibiotics for the treatment of acute exacerbation of chronic obstructive pulmonary disease? A therapeutic outcomes model. J of Antimicrob Chemother 2007; 60: 605–12.
27. Thornsberry C, Sahm D, Kelly L et al. Regional trends in antimicrobial resistance among clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States: results from the TRUST Surveillance Program, 1999–2000. Clin Infect Dis 2002; 34 (Suppl. 1): 4–16.
28. Jacobs M, Felmingham D, Appelbaum P et al. The Alexander Project 1998–2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. J Antimicrob Chemother 2003; 52 (2): 229–46.
29. Козлов Р.С., Сивая О.В., Шпынев К.В. и др. Антибиотикорезистентность Streptococcus pneumoniae в России в 1999–2005 гг.: результаты многоцентровых проспективных исследований Пегас I и Пегас II. Клин. микробиол. антимикроб. химиотер. 2006; 8 (1): 33–47.
30. White A, Kaye1 C, Poupard J et al. Augmentin® (amoxicillin/clavulanate) in the treatment of community-acquired respiratory tract infection: a review of the continuing development of an innovative antimicrobial agent. J Antimicrob Chemother 2004; 53 (Suppl. 1): 3–20.
31. Calvo A, Amores R, Valero E et al. Activity of different antimicrobial agents against penicillin-resistant Streptococcus pneumoniae. Rev Esp Quimioter 2001; 14: 345–50.
32. Eller J, Ede A, Schaberg T et al. Infective exacerbations of chronic bronchitis: relation between bacteriologic etiology and lung function. Chest 1998; 113: 1542–8.
33. Siempos I, Dimopoulos G, Korbila I et al. Macrolides, quinolones, and amoxicillin/clavulanate for chronic bronchitis: a meta-analysis. Eur Respir J 2007; Доступно на: http://www.antibiotic.ru/print.php?sid=1538
34. Синопальников А.И., Козлов Р.С., Романовских А.Г., Рачина С.А. Инфекционное обострение ХОБЛ: практические рекомендации по диагностике, лечению и профилактике. Рос. мед. вести. 2006; XI (№1): 4–18.
35. Рачина С.А., Зайцев А.А. Фармакоэпидемиологические исследования антибактериальных препаратов при внебольничных инфекциях дыхательных путей. Глава в книге: Руководство для врачей «Внебольничные инфекции дыхательных путей: диагностика и лечение». М.: М-Вести, 2008.
36. Рачина С.А., Фокин А.А., Ишмухаметов А.А. и др. Анализ динамики поквартального потребления антибактериальных препаратов для системного применения в амбулаторном и госпитальном секторах в РФ в 2004 г. Ремедиум. 2006; 11: 24–9.
37. Ferech M, Coenen S, Dvorakova K et al. European Surveillance of Antimicrobial Consumption (ESAC): outpatient penicillin use in Europe. J Antimicrob Chemother 2006; 58 (2): 408–12.
38. Metz-Gercek S, Maieron A, Strau R et al. Ten years of antibiotic consumption in ambulatory care: Trends in prescribing practice and antibiotic resistance in Austria. BMC Infectious Diseases 2009. Доступно на: http://www.biomedcentral.com/1471–2334/9/61.
Авторы
А.А.Зайцев
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.